“Pharmacoeconomics needs to be adopted by countries to focus more on innovation” – Cadila Pharmaceuticals and ISCR organizes session on Pharmacoeconomics

18^th October 2020: Cadila Pharmaceuticals in association with Indian Society for Clinical Research (ISCR) organized a webinar on “Pharmacoeconomics in Drug development and Medicine Accessibility” on 18th October, 2020 which saw the participation from some of the industry leaders from DCGI, ISCR and international academicians.

The session was a mix of industry and academic insights which talked about Pharmacoeconomics, role of Pharmacoeconomics in innovative drug development and Pharmacoeconomics as a tool to enable medicine accessibility. The session saw the participation from –  Dr Rubina Bose, Deputy DCGI, Dr Sanish Davis, General Secretary of Indian Society for Clinical Research (ISCR), Dr Subhrojyoti Bhowmick, Clinical Director, Peerless Hospital, Dr Amogh Dev Rai, Executive Director, Sanrachna, Dr Bakulesh Khamar, Executive Director-R&D at Cadila Pharmaceuticals Ltd. and Prof (Dr) Marcin Czech, Head of the dept. of Pharmacoeconomics, Institute of Mother and Child, Warsaw and ex-Deputy Minister of Health, Government of Poland who was the key note speaker.

“To achieve the public health objectives of national and global government, we need a strong regulatory system. In case of an inefficient regulatory system, it becomes a barrier to making quality and affordable medicines available to all” said Dr Rubina Bose, Deputy DCGI on the relevance of regulatory systems in the current scenario.

“Pharmacoeconomics helps us make an informed decision regarding the appropriate use of drug. It helps us make the best use of limited resources and extend quality healthcare to maximum people” Dr Subhrojyoti Bhowmick, Clinical Director, Peerless Hospital shared.

“ISCR is always working towards innovation and I am grateful to be a part of this conclave to ideate more on working towards affordable healthcare for all” shared Dr Sanish Davis, General Secretary of Indian Society for Clinical Research (ISCR).

“Pricing of drugs is an important factor for any country’s pharmaceutical industry. But we as a country need a clear strategy and need to learn from global industries, to move forward” shared Mr. Amogh Rai, Executive Director, Sanrachna.

“Pharmacoeconomics plays an important role in innovative drug development. It helps with health-care policy decisions, provides guidance for funding of projects and creates demand/awareness. This collectively will enable the pharma organizations to provide innovating drugs at affordable price” shared Dr Bakulesh Khamar, Executive director, Cadila Pharmaceuticals Ltd.

“Globally, there is limited budget for drugs. With Pharmacoeconomics, we want to enable the pharmaceutical industries to focus more on innovation while keeping the pricing in check” shared Prof (Dr) Marcin Czech, Head of the Dept. of Pharmacoeconomics, Institute of Mother and Child, Warsaw and ex-Deputy Minister of Health, Government of Poland.

The session concluded with an engaging question and answer round where doctors and viewers talked about the future of Pharmacoeconomics and how can it change the landscape of the pharma industry. The session can be viewed here -(https://www.facebook.com/watch/live/?v=353393889110743&ref=watch_permalink).

Cadila Pharmaceuticals Ltd. (www.cadilapharma.com) is one of the largest privately-held pharmaceutical companies in India. It has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world. Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.